This opportunity is currently closed.
Sign up for Content alerts to stay informed when this or related funding opportunities are posted.
Translation of Hypoimmunogenic Beta/Islet Cell Sources into Late Preclinical/Clinical Testing for Cell Therapies in T1D (diabetes | worldwide)
The Translation of Hypoimmunogenic Beta/Islet Cell Sources into Late Preclinical/Clinical Testing for Cell Therapies in T1D from the Juvenile Diabetes Research Foundation (JDRF) supports the advancement of early preclinical stage hypoimmunogenic pluripotent stem cells (PSCs) for beta cell replacement in type 1 diabetes (T1D) into late preclinical or pilot clinical testing. Applicants to this RFA should have demonstrated expertise developing discovery and early preclinical stage beta/islet cell sources with the potential for translation of these technologies for T1D beta cell replacement therapies. Applications are open to non-profit and for-profit entities such as academic institutions and industry partners. Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.
Applicants may apply for up to 1 million over 3 years, including 10% indirect costs.
Letters of intent are due on September 5, 2023. Full applications must be submitted by October 10, 2023.
October 10, 2023